{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:28:00Z","timestamp":1791167280577,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T00:00:00Z","timestamp":1287360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Acute myeloid leukemia (AML) in first relapse is associated with a poor outcome even when treated with intermediate\u2010 to high\u2010dose cytarabine (IHDAraC). Gemtuzumab ozogamycin (GO) used as a single agent has clinical activity in relapsed and refractory AML. Various combination regimens of GO have been developed, but few data are available regarding their efficacy compared with IHDAraC\u2010based regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The authors performed a retrospective analysis of response and survival in 90 AML patients in first relapse treated with either IHDAraC (n = 56) or IHDAraC + GO (n = 34). Patient characteristics of the two groups were comparable.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Median follow\u2010up was 37 months. Compared with IHDAraC, IHDAraC + GO induction was associated with a better response rate (68% vs 45%, <jats:italic>P<\/jats:italic> = .04), a better overall survival (median, 35 months vs 6 months, <jats:italic>P<\/jats:italic> = .001), and a better event\u2010free survival (24 months vs 6 months, <jats:italic>P<\/jats:italic> = .002). This effect was limited to patients with low\u2010risk and intermediate\u2010risk cytogenetics. In multivariate analysis, age, cytogenetic risk, first complete remission duration, and the use of IHDAraC + GO were independently associated with better results.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>This study showed that the addition of GO to IHDAraC is associated with a better efficacy for patients in first relapse of AML with low\u2010 or intermediate\u2010risk cytogenetics. Prospective controlled studies of GO in this population are warranted. Patients with high\u2010risk cytogenetics should be offered investigational new drugs. Cancer 2011. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25554","type":"journal-article","created":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T10:29:32Z","timestamp":1287397772000},"page":"974-981","source":"Crossref","is-referenced-by-count":18,"title":["Improved outcome of patients with low\u2010 and intermediate\u2010risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine"],"prefix":"10.1002","volume":"117","author":[{"given":"Thomas","family":"Prebet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"D'incan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Esterni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Arnoulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,10,18]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1182\/blood.V93.9.3149","article-title":"Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy","volume":"93","author":"Vey N","year":"1999","journal-title":"Blood."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.027"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401568"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05318.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.1985.3.7.992","article-title":"High\u2010dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia","volume":"3","author":"Herzig RH","year":"1985","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3244"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08095.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9764"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11239"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3821"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_7_14_2","first-page":"1491","article-title":"Prognostic significance of karyotype in de novo adult acute myeloid leukemia","volume":"9","author":"Dastugue N","year":"1995","journal-title":"The BGMT group. Leukemia."},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.7.1210"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.02.005"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21723"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07917.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21545"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-229351"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23816"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood.V114.22.484.484","article-title":"Attempts to optimise induction and consolidation chemotherapy in patients with acute myeloid leukaemia: results of the MRC AML15 Trial","volume":"114","author":"Burnett A","year":"2009","journal-title":"Blood"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3527"},{"key":"e_1_2_7_25_2","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V114.22.2056.2056","article-title":"Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G\u2010CSF and Gemtuzumab Ozogamicin","volume":"114","author":"Borthakur G","year":"2009","journal-title":"Blood."},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06646.x"},{"key":"e_1_2_7_27_2","first-page":"4589","article-title":"The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro","volume":"29","author":"Tanaka M","year":"2009","journal-title":"Anticancer Res."},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.153"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25554","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:21:16Z","timestamp":1760300476000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25554"}},"subtitle":["Results of a retrospective comparative study"],"short-title":[],"issued":{"date-parts":[[2010,10,18]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1002\/cncr.25554"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25554","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,18]]}}}